SLNP-based CDK4- targeted nanotherapy against glioblastoma.

ABSTRACT:

Introduction

Glioblastoma is a grade IV solid brain tumor and has a 15-month survival rate even after treatment. Glioblastoma development is heavily influenced by retinoblastoma protein (pRB) pathway changes. The blood-brain barrier, drug resistance, and severe toxicity of Temozolamide are key obstacles in treating glioblastoma. Innovative treatments targeting the pRB pathway with efficient delivery vehicles are required to treat glioblastoma.

Methods

For this purpose, a library of 691 plant extracts previously tested in vitro for anti-cancerous, anti inflammatory, and anti-proliferative characteristics was created after thorough literature investigations. Compounds were docked against pRB pathway protein ligands using molecular operating environment and chimera. Thei

SUBMITTER: Ghani U 

PROVIDER: S-EPMC11621005 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature